Sangamo Therapeutics Inc has a consensus price target of $5.17 based on the ratings of 9 analysts. The high is $10 issued by HC Wainwright & Co. on April 7, 2025. The low is $1.5 issued by B of A Securities on April 28, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., RBC Capital, and HC Wainwright & Co. on April 7, 2025, March 18, 2025, and January 27, 2025, respectively. With an average price target of $7.33 between HC Wainwright & Co., RBC Capital, and HC Wainwright & Co., there's an implied 865.29% upside for Sangamo Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/07/2025 | Buy Now | 1216.31% | HC Wainwright & Co. | Patrick Trucchio41% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
03/18/2025 | Buy Now | 163.26% | RBC Capital | Luca Issi36% | $2 → $2 | Reiterates | Sector Perform → Sector Perform | Get Alert |
01/27/2025 | Buy Now | 1216.31% | HC Wainwright & Co. | Patrick Trucchio41% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
01/23/2025 | Buy Now | 558.15% | Truist Securities | Nicole Germino36% | $7 → $5 | Maintains | Buy | Get Alert |
01/02/2025 | Buy Now | 1216.31% | HC Wainwright & Co. | Patrick Trucchio41% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
12/31/2024 | Buy Now | 294.89% | Jefferies | Maury Raycroft31% | $7 → $3 | Maintains | Buy | Get Alert |
12/31/2024 | Buy Now | 163.26% | Wells Fargo | Jim Birchenough62% | $3 → $2 | Maintains | Equal-Weight | Get Alert |
12/20/2024 | Buy Now | 1216.31% | HC Wainwright & Co. | Patrick Trucchio41% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
12/19/2024 | Buy Now | 1216.31% | HC Wainwright & Co. | Patrick Trucchio41% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
12/10/2024 | Buy Now | 1216.31% | HC Wainwright & Co. | Patrick Trucchio41% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
11/14/2024 | Buy Now | 1216.31% | HC Wainwright & Co. | Patrick Trucchio41% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
11/14/2024 | Buy Now | 1084.68% | Barclays | Gena Wang50% | $3 → $9 | Maintains | Overweight | Get Alert |
11/05/2024 | Buy Now | 1216.31% | HC Wainwright & Co. | Patrick Trucchio41% | $5 → $10 | Maintains | Buy | Get Alert |
10/23/2024 | Buy Now | 558.15% | HC Wainwright & Co. | Patrick Trucchio41% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
10/22/2024 | Buy Now | 558.15% | HC Wainwright & Co. | Patrick Trucchio41% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
08/22/2024 | Buy Now | 558.15% | HC Wainwright & Co. | Patrick Trucchio41% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
07/31/2024 | Buy Now | 558.15% | HC Wainwright & Co. | Patrick Trucchio41% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
07/24/2024 | Buy Now | 558.15% | HC Wainwright & Co. | Patrick Trucchio41% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
05/15/2024 | Buy Now | 558.15% | HC Wainwright & Co. | Patrick Trucchio41% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
03/19/2024 | Buy Now | 558.15% | HC Wainwright & Co. | Patrick Trucchio41% | $3 → $5 | Reiterates | Buy → Buy | Get Alert |
03/14/2024 | Buy Now | 163.26% | RBC Capital | Luca Issi36% | $2 → $2 | Reiterates | Sector Perform → Sector Perform | Get Alert |
03/13/2024 | Buy Now | 294.89% | HC Wainwright & Co. | Patrick Trucchio41% | $3 → $3 | Maintains | Buy | Get Alert |
02/12/2024 | Buy Now | 294.89% | HC Wainwright & Co. | Patrick Trucchio41% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
02/06/2024 | Buy Now | 294.89% | HC Wainwright & Co. | Patrick Trucchio41% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
01/19/2024 | Buy Now | 294.89% | HC Wainwright & Co. | Patrick Trucchio41% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
11/07/2023 | Buy Now | — | Truist Securities | Nicole Germino36% | — | Downgrade | Buy → Hold | Get Alert |
11/06/2023 | Buy Now | 294.89% | HC Wainwright & Co. | Patrick Trucchio41% | $5 → $3 | Maintains | Buy | Get Alert |
11/06/2023 | Buy Now | 31.63% | Wells Fargo | Jim Birchenough62% | → $1 | Downgrade | Overweight → Equal-Weight | Get Alert |
11/03/2023 | Buy Now | 163.26% | RBC Capital | Luca Issi36% | $6 → $2 | Downgrade | Outperform → Sector Perform | Get Alert |
08/15/2023 | Buy Now | 821.42% | Truist Securities | Nicole Germino36% | $8 → $7 | Maintains | Buy | Get Alert |
08/14/2023 | Buy Now | 558.15% | HC Wainwright & Co. | Patrick Trucchio41% | → $5 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | Buy Now | 1216.31% | Wedbush | Andreas Argyrides69% | $16 → $10 | Maintains | Outperform | Get Alert |
08/10/2023 | Buy Now | 426.52% | Wells Fargo | Yanan Zhu36% | $5 → $4 | Maintains | Overweight | Get Alert |
08/09/2023 | Buy Now | 1084.68% | Barclays | Gena Wang50% | $11 → $9 | Maintains | Overweight | Get Alert |
08/09/2023 | Buy Now | 689.79% | RBC Capital | Luca Issi36% | $8 → $6 | Maintains | Outperform | Get Alert |
05/10/2023 | Buy Now | 953.05% | Truist Securities | Nicole Germino36% | $16 → $8 | Maintains | Buy | Get Alert |
05/01/2023 | Buy Now | 558.15% | HC Wainwright & Co. | Patrick Trucchio41% | $15 → $5 | Maintains | Buy | Get Alert |
04/28/2023 | Buy Now | 97.45% | B of A Securities | Greg Harrison40% | $5 → $1.5 | Downgrade | Neutral → Underperform | Get Alert |
03/03/2023 | Buy Now | 1874.46% | HC Wainwright & Co. | Patrick Trucchio41% | $25 → $15 | Maintains | Buy | Get Alert |
02/27/2023 | Buy Now | 2006.09% | Wedbush | Andreas Argyrides69% | → $16 | Upgrade | Neutral → Outperform | Get Alert |
02/23/2023 | Buy Now | 1611.2% | RBC Capital | Luca Issi36% | $22 → $13 | Maintains | Outperform | Get Alert |
01/04/2023 | Buy Now | 1874.46% | Wells Fargo | Yanan Zhu36% | $20 → $15 | Maintains | Overweight | Get Alert |
11/07/2022 | Buy Now | 2532.62% | Wells Fargo | Yanan Zhu36% | $22 → $20 | Maintains | Overweight | Get Alert |
06/13/2022 | Buy Now | 558.15% | Wedbush | Andreas Argyrides69% | → $5 | Assumes | → Neutral | Get Alert |
The latest price target for Sangamo Therapeutics (NASDAQ:SGMO) was reported by HC Wainwright & Co. on April 7, 2025. The analyst firm set a price target for $10.00 expecting SGMO to rise to within 12 months (a possible 1216.31% upside). 19 analyst firms have reported ratings in the last year.
The latest analyst rating for Sangamo Therapeutics (NASDAQ:SGMO) was provided by HC Wainwright & Co., and Sangamo Therapeutics reiterated their buy rating.
The last upgrade for Sangamo Therapeutics Inc happened on February 27, 2023 when Wedbush raised their price target to $16. Wedbush previously had a neutral for Sangamo Therapeutics Inc.
The last downgrade for Sangamo Therapeutics Inc happened on November 7, 2023 when Truist Securities changed their price target from N/A to N/A for Sangamo Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on April 7, 2025 so you should expect the next rating to be made available sometime around April 7, 2026.
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a reiterated with a price target of $10.00 to $10.00. The current price Sangamo Therapeutics (SGMO) is trading at is $0.76, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.